Brian Pochini

Sanofi
Principal Engineer
Brian Pochini is a Building and Clean Utilities Design Lead working in Sanofi Global Engineering. Brian has a Bachelor’s Degree in Chemical Engineering; a Master’s in Business Administration and is a Certified Pharmaceutical Industry Professional (CPIP). Brian has over 20 years’ practical experience within biotechnology, membrane manufacturing/development and custom chemical industries. Brian has a diverse background encompassing multiple engineering discipline functions including HVAC, Critical Utilities, Process Engineering, Instrumentation & Controls, and Facility Design. He has experience in all project phases, including conceptual engineering, basic engineering, detailed design, equipment procurement, construction, facility and equipment start-up, and commissioning and qualification activities. Additionally, his project management experience includes the simultaneous management of multiple capital projects and cross-functional team management. He is a current member of the ISPE Guidance Document Committee (GDC) and a former member of the ISPE FOYA Committee, the former secretary/co-chair for the ISPE Knowledge Network Council, a former member of the ISPE Commissioning & Qualification Steering Committee, a current member of the ISPE Critical Utilities Steering Committee. Brian has been a contributing author, chapter lead and guide lead for multiple ISPE guides across varying disciplines. Currently he is co-leading the revision of the ISPE Good Practice Guide: Sampling Pharma Water, Steam, & Process Gases and is a contributing author for anew ISPE guide regarding Sustainable Critical Utility Systems

Related Articles

Is a Membrane-Based Water for Injection System Right for Your Facility?
iSpeak Blog
Is a Membrane-Based Water for Injection System Right for Your Facility?

For nearly a century, production of Water for Injection (WFI) was universally accepted to be distillation-based. As emphasis on costs and environmental concerns has grown, pharmacopeias around the world have focused on the quality attributes of WFI to allow for consideration of other production technologies. In 2017, the European Pharmacopoeia joined the US, Japan, and many other regulatory...